Enanta Pharmaceuticals Statistics
Share Statistics
Enanta Pharmaceuticals has 21.19M shares outstanding. The number of shares has increased by 0.63% in one year.
| Shares Outstanding | 21.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.73M |
| Failed to Deliver (FTD) Shares | 5 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.44M, so 16.24% of the outstanding shares have been sold short.
| Short Interest | 3.44M |
| Short % of Shares Out | 16.24% |
| Short % of Float | 17.46% |
| Short Ratio (days to cover) | 20.91 |
Valuation Ratios
The PE ratio is -1.89 and the forward PE ratio is -2.21.
| PE Ratio | -1.89 |
| Forward PE | -2.21 |
| PS Ratio | 3.24 |
| Forward PS | 1.7 |
| PB Ratio | 1.7 |
| P/FCF Ratio | -2.27 |
| PEG Ratio | n/a |
Enterprise Valuation
Enanta Pharmaceuticals Inc. has an Enterprise Value (EV) of 175.35M.
| EV / Earnings | -1.51 |
| EV / Sales | 2.59 |
| EV / EBITDA | -1.68 |
| EV / EBIT | -1.44 |
| EV / FCF | -1.81 |
Financial Position
The company has a current ratio of 5.21, with a Debt / Equity ratio of 0.43.
| Current Ratio | 5.21 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.43 |
| Total Debt / Capitalization | 30.1 |
| Cash Flow / Debt | -1.42 |
| Interest Coverage | -11.12 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -65.06%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -65.06% |
| Revenue Per Employee | 466.45K |
| Profits Per Employee | -800.31K |
| Employee Count | 145 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.74M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -35.12% in the last 52 weeks. The beta is 0.57, so Enanta Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -35.12% |
| 50-Day Moving Average | 10.27 |
| 200-Day Moving Average | 12.67 |
| Relative Strength Index (RSI) | 22.73 |
| Average Volume (20 Days) | 241.22K |
Income Statement
In the last 12 months, Enanta Pharmaceuticals had revenue of $67.64M and earned -$116.05M in profits. Earnings per share was $-5.48.
| Revenue | 67.64M |
| Gross Profit | 67.64M |
| Operating Income | -121.69M |
| Net Income | -116.05M |
| EBITDA | -104.51M |
| EBIT | -121.69M |
| Earnings Per Share (EPS) | -5.48 |
Balance Sheet
The company has $37.23M in cash and $55.47M in debt, giving a net cash position of -$18.23M.
| Cash & Cash Equivalents | 37.23M |
| Total Debt | 55.47M |
| Net Cash | -18.23M |
| Retained Earnings | -323.04M |
| Total Assets | 376.65M |
| Working Capital | 242.32M |
Cash Flow
In the last 12 months, operating cash flow was -$78.76M and capital expenditures -$17.95M, giving a free cash flow of -$96.71M.
| Operating Cash Flow | -78.76M |
| Capital Expenditures | -17.95M |
| Free Cash Flow | -96.71M |
| FCF Per Share | -4.57 |
Margins
Gross margin is 100%, with operating and profit margins of -179.92% and -171.58%.
| Gross Margin | 100% |
| Operating Margin | -179.92% |
| Pretax Margin | -174.15% |
| Profit Margin | -171.58% |
| EBITDA Margin | -154.52% |
| EBIT Margin | -179.92% |
| FCF Margin | -142.99% |
Dividends & Yields
ENTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -90.43% |
| FCF Yield | -75.3% |
Analyst Forecast
The average price target for ENTA is $20.5, which is 238.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.5 |
| Price Target Difference | 238.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -0.86 |
| Piotroski F-Score | 3 |